INTS

Business Context and Reporting Period

Company: Intensity Therapeutics, Inc. (INTS)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2024
Business Overview: A late-stage clinical biotechnology company developing intratumoral cancer therapies using its DfuseRx platform. The lead product candidate, INT230-6, is a combination of cisplatin, vinblastine sulfate, and an amphiphilic molecule designed to treat solid tumors. The Company has no product revenue and is focused on advancing clinical trials.

Key Financial Metrics

Liquidity: As of September 30, 2024, the Company held $2.8 million in cash and cash equivalents. There were no marketable debt securities remaining as of this date (down from $6.2 million at year-end 2023). The Company has no long-term debt outstanding.

Material Changes vs. Prior Period

• Increased Operating Expenses: Total operating expenses for the nine months ended September 30, 2024, increased by $8.4 million (169%) compared to the same period in 2023.
  • R&D Expenses: Increased by $5.5 million (186%) primarily due to the initiation of the Phase 3 INVINCIBLE-3 Study and increased clinical trial costs, partially offset by lower costs in completed studies.
  • G&A Expenses: Increased by $2.9 million (145%) driven by higher salaries (including a new CFO), increased stock-based compensation, and higher insurance and legal fees associated with public company operations.
• Net Loss Expansion: Net loss for the nine months ended September 30, 2024, increased by $5.7 million compared to the prior year period, reflecting the surge in operational spending.
• Cash Position: Cash and cash equivalents decreased by $5.8 million during the nine-month period, driven by a net cash burn of $12.6 million from operations, partially offset by $6.4 million provided by investing activities (redemption of marketable securities).

Guidance, Outlook, and Risks

Clinical Progress:

• INVINCIBLE-3 (Phase 3): Initiated in July 2024 for soft tissue sarcoma subtypes; first patients dosed in the U.S. Authorization received for Canada and Europe.
• INVINCIBLE-4 (Phase 2): Initiated in October 2024 for early-stage triple-negative breast cancer; first patient dosed.

Liquidity and Going Concern:

• The Company explicitly states there is substantial doubt about its ability to continue as a going concern.
• Management projects sufficient cash to fund operations only into the first quarter of 2025.
• The Company has no committed external funding and expects to require significant additional capital to complete clinical trials and achieve profitability.

Internal Controls:

• Management concluded that disclosure controls and procedures were not effective as of September 30, 2024, due to material weaknesses including lack of segregation of duties, limited reconciliation of clinical accruals, and IT user access issues.
• Remediation efforts are underway, including hiring a new CFO and engaging technical consultants.

Other Risks:

• Patent Risks: The Company holds a patent in Russia (payments due through 2025) and a patent in Israel (currently in a conflict zone), creating potential risks of loss or inability to enforce rights.
• Dilution: Future equity or debt financings will likely result in significant dilution to existing shareholders.

Investor Verification Checklist

• Cash Runway: Verify the accuracy of the projection that cash will last only into Q1 2025 given the high burn rate ($12.6M over 9 months).
• Financing Plans: Confirm if any new financing agreements (equity or debt) have been secured since the filing date to bridge the funding gap.
• Internal Control Remediation: Monitor the progress of remediation for the identified material weaknesses in internal controls over financial reporting.
• Clinical Trial Costs: Assess the scalability of R&D expenses as the Phase 3 INVINCIBLE-3 study expands to eight countries.
• Intellectual Property: Evaluate the specific risks associated with the patents held in Russia and Israel and potential mitigation strategies.